[DOI] [PMC free article] [PubMed] [Google Scholar] 137.Seminer A, et al
Researchers initially investigated it as a potential treatment for obesity and metabolic disorders
A potential paradigm shift in managing severe hypertriglyceridemia and metabolic liver disease beyond GLP-1 therapy
The 28.7% figure for retatrutide comes from TRIUMPH-4, a Phase 3 trial of 445 adults living with obesity and knee osteoarthritis, reported by Lilly in a December 2025 press release
Metabolic Health Improvements Researchers are also examining potential benefits related to: Blood sugar regulation Insulin sensitivity Fat metabolism However, long-term safety and effectiveness still require further investigation
Section 503A of the Federal Food, Drug, and Cosmetic Act allows licensed pharmacies to compound prescription medications when those medications are unavailable from the manufacturer (e.g., on FDAs shortage list) or when a patient needs a customized formulation that the commercial product cannot provide (such as a different concentration, an additive like B12, or an allergen-free form)
